Details

Autor(en) / Beteiligte

• Taniguchi, Masami
• Heffler, Enrico
• Olze, Heidi
• White, Andrew
• Côrte-Real, Joana
• Olsson, Petter
• Lazarewicz, Slawomir

Titel

The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review

Ist Teil von

• The journal of allergy and clinical immunology in practice (Cambridge, MA), 2022-10, Vol.10 (10), p.2570-2578

Ort / Verlag

Amsterdam: Elsevier Inc

Erscheinungsjahr

2022

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Nonsteroidal anti-inflammatory drug–exacerbated respiratory disease (N-ERD) is a condition characterized by the triad of chronic rhinosinusitis with nasal polyps, bronchial asthma, and hypersensitivity to nonsteroidal anti-inflammatory drugs. This article explores the current knowledge on the various pathological mechanism(s) of N-ERD—such as arachidonic acid metabolism, cysteinyl leukotrienes, prostaglandins, platelets, IgE, mast cells, eosinophils, basophils, and innate immune system—and the role of omalizumab in its management. The authors dive deep into the role of IgE in N-ERD and its potential as a therapeutic target. IgE plays a significant role in mediating allergic reactions, is intricately linked with mast cells, interacts with multiple immunopathological pathways involved in N-ERD, and tends to be elevated in patients with N-ERD. Multiple real-world studies, observational studies, and case series, as well as 2 phase III trials, have demonstrated the effectiveness of omalizumab in the management of N-ERD. For a disease with such a well-documented history, the pathophysiology of N-ERD and the most effective ways to manage it remain a mystery. With this background, the authors ask—is IgE a missing piece of the N-ERD puzzle, thus explaining the efficacy of omalizumab in the treatment of the disease?